Key features and details
- Mouse monoclonal [NCM II 100] to n-Myc/MYCN
- Suitable for: IP, Flow Cyt
- Reacts with: Mouse, Human
- Isotype: IgG1
Product nameAnti-n-Myc/MYCN antibody [NCM II 100]
See all n-Myc/MYCN primary antibodies
DescriptionMouse monoclonal [NCM II 100] to n-Myc/MYCN
This antibody reacts with N-myc/MYCN encoded proteins and their cleavage products.
Tested applicationsSuitable for: IP, Flow Cytmore details
Species reactivityReacts with: Mouse, Human
Fusion protein corresponding to Human n-Myc/MYCN. Recombinant fusion protein. Original clone reference: PubMed ID - 2426708.
Database link: P04198
- IMR5 Cells
It is important to compensate for the short half life of this protein when preparing tissue sections or extracts. We recommended that all preparations be kept cold and that a cocktail of protease inhibitors be used.
This product was previously labelled as n-Myc
This product was changed from ascites to tissue culture supernatant on 17 May 2019. Please note that the dilutions may need to be adjusted accordingly. If you have any questions, please do not hesitate to contact our scientific support team.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
Storage bufferConstituents: 0.82% Sodium phosphate, 50% Glycerol
Concentration information loading...
PurityTissue culture supernatant
Purification notesPurified from TCS.
Clone numberNCM II 100
Light chain typekappa
ChIP Related Products
Our Abpromise guarantee covers the use of ab16898 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IP||Use at an assay dependent concentration.|
|Flow Cyt||Use at an assay dependent concentration.
ab170190 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.
FunctionMay function as a transcription factor.
Involvement in diseaseNote=Amplification of the N-MYC gene is associated with a variety of human tumors, most frequently neuroblastoma, where the level of amplification appears to increase as the tumor progresses.
Defects in MYCN are the cause of microcephaly-oculo-digito-esophageal-duodenal syndrome (MODED) [MIM:164280]; also known as oculodigitoesophagoduodenal syndrome (ODED). Microcephaly-oculo-digito-esophageal-duodenal syndrome is characterized by variable combinations of esophageal and duodenal atresias, microcephaly, learning disability and limb malformations. Cardiac and renal malformations, vertebral anomalies, and deafness have also been described.
Defects in MYCN are the cause of microcephaly and digital abnormalities with normal intelligence (MCPHDANI) [MIM:602585].
Sequence similaritiesContains 1 basic helix-loop-helix (bHLH) domain.
Developmental stageExpressed during fetal development.
- Information by UniProt
- bHLHe37 antibody
- Class E basic helix-loop-helix protein 37 antibody
- MODED antibody
ab16898 has been referenced in 31 publications.
- Almstedt E et al. Integrative discovery of treatments for high-risk neuroblastoma. Nat Commun 11:71 (2020). PubMed: 31900415
- Song H et al. HNF4A-AS1/hnRNPU/CTCF axis as a therapeutic target for aerobic glycolysis and neuroblastoma progression. J Hematol Oncol 13:24 (2020). PubMed: 32216806
- Santiago T et al. Correlation Between MYCN Gene Status and MYCN Protein Expression in Neuroblastoma: A Pilot Study To Propose the Use of MYCN Immunohistochemistry in Limited-Resource Areas. J Glob Oncol 5:1-7 (2019). IHC-P ; Human . PubMed: 31365300
- Maresch CC et al. Hyperglycemia induces spermatogenic disruption via major pathways of diabetes pathogenesis. Sci Rep 9:13074 (2019). PubMed: 31506549
- Sun Q et al. SEMA6D regulates perinatal cardiomyocyte proliferation and maturation in mice. Dev Biol 452:1-7 (2019). PubMed: 31042497